SummitTX Capital’s Compass Therapeutics CMPX Stock Holding History

SummitTX Capital’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-81,449	Closed	-$437K	–	805
2025 Q4	$437K	Buy	+81,449	New	+$376K	0.01%	547

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SummitTX Capital's CMPX Position: Q1 2026 in Review

SummitTX Capital sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 81,449 shares — an estimated $437K sold.

SummitTX Capital first reported a position in CMPX in Q4 2025 and held it in 1 quarter. The position peaked at $437K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

SummitTX Capital reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
SummitTX Capital sold 81,449 Compass Therapeutics shares in Q1 2026, an estimated $437K.
SummitTX Capital first reported a position in Compass Therapeutics in Q4 2025 and held it in 1 quarter.
SummitTX Capital's Compass Therapeutics position peaked at $437K in Q4 2025.
201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.